Race Oncology (ASX:RAC) has announced it has been issued a new patent (US 11,135,201) from the US Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene (bisantrene dihydrochloride).
The company said this is the fifth patent granted for Zantrene in the US.
“This latest US patent provides Race with additional protection around the use, formulation and compositions of Zantrene (and related chemical structures) that improve the therapeutic benefit of Zantrene,” said Race CEO and managing director, Phillip Lynch.
The company said the new patent builds on its existing Zantrene patents granted in the US in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192) and in 2020 (US 10,548,876), further strengthening its intellectual property position for Zantrene.
"The patent further expands Race’s IP portfolio in the therapeutic utility of Zantrene (and related chemical structures), in particular – for methods, formulations and compositions that improve the therapeutic efficacy of Zantrene and reduce side effects," added the company.